Abstract
Discoidin domain receptor tyrosine kinases (DDRs) are a class of receptor tyrosine kinases (RTKs), and their dysregulation is associated with multiple diseases (including cancer, chronic inflammatory conditions, and fibrosis). The DDR family members (DDR1a-e and DDR2) are widely expressed, with predominant expression of DDR1 in epithelial cells and DDR2 in mesenchymal cells. Structurally, DDRs consist of three regions (an extracellular ligand binding domain, a transmembrane domain, and an intracellular region containing a kinase domain), with their kinase activity induced by receptor-specific ligand binding. Collagen binding to DDRs stimulates DDR phosphorylation activating kinase activity, signaling to MAPK, integrin, TGF-β, insulin receptor, and Notch signaling pathways. Abnormal DDR expression is detected in a range of solid tumors (including breast, ovarian, cervical liver, gastric, colorectal, lung, and brain). During tumorigenesis, abnormal activation of DDRs leads to invasion and metastasis, via dysregulation of cell adhesion, migration, proliferation, secretion of cytokines, and extracellular matrix remodeling. Differential expression or mutation of DDRs correlates with pathological classification, clinical characteristics, treatment response, and prognosis. Here, we discuss the discovery, structural characteristics, organizational distribution, and DDR-dependent signaling. Importantly, we highlight the key role of DDRs in the development and progression of breast and ovarian cancer.
Introduction
Breast and ovarian cancer are amongst the most common female malignancies, with a history of breast cancer linked to a higher risk of ovarian cancer (Mahumud et al., 2019). Recent advances in medical science, including earlier detection and targeted treatments, have significantly increased survival in many cancers, including breast and ovarian (Matchett et al., 2017; Prakash et al., 2018; Siegel et al., 2020). The primary treatment of solid tumors is surgical excision combined with other therapeutic approaches, including systemic chemotherapy, radiation therapy and targeted therapies (including immunotherapies and drugs targeting disease specific mutations or proteins). However, further improvements in treatment efficacy and specificity are needed (Li et al., 2019; Momenimovahed et al., 2019). Targeted molecular therapy is a promising strategy utilized to impede cancer cell growth, invasion or metastasis by targeting the unique genetic, proteomic or epigenetic profile of individual tumors. The discovery, and understanding the mechanism of action, of novel target molecules dysregulated in female malignancies is central to the development of truly personalized cancer treatments needed to improve patient survival (; Sapiezynski et al., 2016; ; Maennling et al., 2019).
Many novel therapeutics target extracellular molecules dysregulated in tumors (e.g., the Her2 receptor in breast cancer). This approach has the advantage of improved target access for drugs, with the therapeutics not requiring cell entry (; Nakhjavani et al., 2019). Importantly, cell to extracellular matrix (ECM) contact (mediated by extracellular receptors) significantly regulates many aspects of tumor cell behavior, including proliferation, apoptosis, basement membrane invasion, and metastases (Marastoni et al., 2008). As a major component of tissue ECM, collagen exhibits disrupted architecture within the tumor microenvironment, and binding of collagen to tumor cells triggers wide-ranging causal effects on tumor development (Xu et al., 2019). Importantly, the direct binding of collagen to tumor cells is mediated by discoidin domain receptor tyrosine kinases (DDRs), a subfamily of the receptor tyrosine kinases (RTKs), which are promising new therapeutic molecular targets.
Receptor Tyrosine Kinase Family: Structure and Characteristics
Protein tyrosine kinases (PTKs) are a class of protein kinases which require tyrosine phosphorylation for activation (Ruckert et al., 2019). Within the PTK superfamily, the RTK family are single transmembrane proteins (with over 20 classes identified), acting as both receptors and enzymes (Figure 1; Lemmon and Schlessinger, 2010). PTKs function as signal transducers, and as critical regulatory factors in many signaling pathways, affecting cell cycle, cell migration, metabolism, survival, and differentiation. RTKs include the DDR family, in addition to insulin receptors, epidermal growth factor receptors (EGFRs), platelet growth factor receptors (PGFRs), fibroblast growth factor receptors (FGFRs), vascular endothelial growth factor receptors, ephrin receptors, hepatocyte growth factor receptor, nerve growth factor receptors, and colon carcinoma kinase receptors (Lemmon and Schlessinger, 2010; ). RTKs have the same structural layout: the extracellular domain (containing a ligand-binding site), the hydrophobic alpha helix region (membrane spanning), and the intra-cellular domain (containing the kinase domain) (). In cancer, many RTKs have been shown to play critical roles in tumorigenesis, development, and metastasis (Figure 2; Yamaoka et al., 2018; ).
FIGURE 1
FIGURE 2
Discoidin Domain Receptor Tyrosine Kinases
Within the RTKs the family of discoidin domain receptor tyrosine kinases (DDRs) are non-integrated collagen receptors, where the extracellular domain contains a discoidin-like domain (or discoidin domain receptor). In mammals, there are two subtypes of DDRs, DDR1 and DDR2, the only RTKs known to interact with structural components of the ECM and in which soluble growth factors do not activate them (Vogel et al., 2006; ). DDR1 and DDR2 function as ECM signal transducers, binding to the ECM collagen, and initiating intra-cellular signaling (). DDRs and their signaling pathways are promising targets for the development of new clinical treatments, particularly in cancers with altered DDR expression or function ().
Discoidin Domain Receptor Tyrosine Kinase Subfamily Discovery
Discoidin domain receptor tyrosine kinase 1 and discoidin domain receptor tyrosine kinase 2 contain a discoidin homology (DS) domain in their extracellular regions. The DDR1 subfamily is composed of five splice-variant isoforms (DDR1a-e) initially discovered in a screen for tyrosine phosphorylation in breast cancer cells (; Takai et al., 2018). The DDR2 subfamily (consisting of DDR2 alone) shares highly conserved sequences with the DDR1 family. The DDRs were initially classed as orphan receptors, until the discovery that many collagens function as their ligands (Shrivastava et al., 1997; Vogel et al., 1997). DDR1 is activated by binding of wide-ranging types of collagen (including collagen I, IV, V, VI, and VIII), whereas DDR2 is exclusively activated by the fibrillar collagens (type I, III, and type X) (Leitinger and Kwan, 2006).
Discoidin Domain Receptor Tyrosine Kinase Protein Structure
The DDR1 gene (6p21.33) contains 17 exons, which generates five DDR1 isoforms through alternative splicing. DDR1a-c are full-length functional receptors, while DDR1d and DDR1e are truncated receptors lacking kinase activity (Figure 3; Rammal et al., 2016). The canonical DDR1 protein contains 8 extracellular regions, 1 transmembrane region, 3 near membrane regions, and 5 tyrosine kinase catalytic regions (Moll et al., 2019). The best studied DDR1 isoforms are DDR1a and DDR1b. Notably, DDR1a is 876 amino acids (aa) long and has a 37 aa deletion in the transmembrane (TM) region and a 6 aa deletion in the kinase domain (KD) region (between exons 13 and 14) (compared to DDR1c). In contrast, DDR1b has an additional 37 aa in the intra-cellular juxtamembrane (IJXM) region. DDR1c is the longest isoform (919 aa), containing both the additional 37 aa in the IJXM, and an additional 6 aa in the kinase domain region. DDR1d is 508 aa long and lacks exons 11 and 12 causing a frameshift mutation that generates a stop codon and loss of the KD. DDR1e is 767 aa long and lacks exons 11 and 12 and the first half of exon 10, generating an inactive KD. In addition, DDR1d and DDR1e are inactive due to a lack of ATP binding sites, and currently have not had a clear biological function assigned to them (Valiathan et al., 2012). DDR1 can be cleaved (by an as yet undetermined protease) into a 54 kb soluble alpha subunit located in the extracellular region, and a 63 kb beta subunit anchored to the membrane (Yeh et al., 2009). DDR1 is activated by recognizing the GVMGVO peptide motif in fibrillar collagens (I, II, III, and VIII), and non-fibrillar basement membrane collagen IV (Xu et al., 2012). The DDR2 gene is located in human 1q23.3, contains 19 exons and encodes a single transcript, and one 855 aa protein (). The DDR2 juxtamembrane (JM) domain is composed of extracellular JM region (approximately 30 aa) followed by large cytosolic JM regions of about 142 aa. The KD is capped by a short C-terminal peptide of about 6 aa.
FIGURE 3
Cellular Expression and Distribution
While the DDR1 protein is primarily expressed in epithelial cells, expression is seen other cell types including the myelin sheath and microglia, keratinocytes, large intestinal epithelia, lung epithelia, breast epithelia, adrenal cortical cells, pancreatic ducts, and thyroid follicles (). Physiologically DDR1 plays a key role in organogenesis, and in breast development (Moll et al., 2019). DDR2 is predominantly expressed in connective tissues of mesenchymal origin, with high expression also seen in the skeletal and heart muscle, as well as kidney and lung cells and immature dendritic cells (constitutive expression) (; Vogel, 1999; ). According to the microenvironment, DDRs can form multiple subcellular complexes, with diverse functions (Figure 4; ; ; ).
FIGURE 4
Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 Mediated Signaling Cascades
Discoidin domain receptor tyrosine kinase 1 and discoidin domain receptor tyrosine kinase 2 are non-integrin receptors acting as sensors of the ECM (activated by fibrillar collagens), mediating signaling which regulates many diverse cellular processes (including proliferation, invasion, migration, differentiation, cytokine secretion, ECM remodeling, and embryonic development) (Figure 5; Orgel and Madhurapantula, 2019; Vanajothi et al., 2019; ). Dysregulated DDR-mediated signaling is strongly associated with many forms of cancer, and has been associated with other diseases (including osteogenesis hypoplasia, and arthritis) (). Overviews of key DDR1 or DDR2-mediated signaling cascades are shown in Figures 6, 7, respectively (Payne and Huang, 2014; ).
FIGURE 5
FIGURE 6
FIGURE 7
Collagen-Mediated Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 Signaling
Collagen stimulation of DDR1 leads to binding and activation of Notch1 increasing cell survival, by promoting the activation of transcription factors (Hcs1 and Hcy2) and the expression of pro-survival genes (though γ-secretase cleavage of the Notch1 intracellular domain, and nuclear localization) (; ). Cell cycle regulated signaling mediates Wnt-5a expression, which can act as an upstream regulator of DDR1, promoting collagen-induced DDR1 phosphorylation and activation, which alters cell adhesion and migration (, ). Collagen - has been demonstrated to trigger DDR1-induced Pyk2 phosphorylation, which induces apoptosis and inhibits epithelial to mesenchymal transition (EMT) (). Furthermore, DDRs have been demonstrated to have a critical role in regulating keloid collagen overproduction, regulating collagen-fibroblast signaling ().
Additionally, DDRs are well known to differentially modulate distinctive mitogen-activated Protein Kinase (MAPK) signaling pathways, transducing extracellular signals and mediating cellular responses to these extracellular stimuli. In mammary epithelial cells and smooth muscle cells, DDR1 activates extracellular signal-regulated protein kinases (ERK)1/2 following extracellular stimulation (Peng et al., 2017). Conversely, in mesangial cells, DDR1 has been shown to inhibit ERK1/2 activation (Moll et al., 2018). DDR1 can mediate downstream signals via c-Jun N-terminal Kinases (JNK), as seen in pancreatic cancer cells (Zhu et al., 2019). Following DNA damage, p53 mediated DDR1 phosphorylation is involved in cell survival or apoptosis decisions, through Ras-Raf-MAPK and Protein kinase B (AKT) signaling (Ongusaha et al., 2003).
Overexpression of DDR1 promotes tumor cell proliferation (including regulating tumor-infiltrating CD4 + and CD8 + T cells), while silencing or knocking out DDR1 can reduce tumor cell growth (Peretti et al., 2019). Overexpression of DDR1/2 in cells expressing integrin α1β1 and α2β1 can enhance the level of integrin activation-mediated cell adhesion (Xu et al., 2012). While integrin β1 promotes cell differentiation by down-regulating E-cadherin expression, DDR1 promotes differentiation by increasing the stability of E-cadherin membrane proteins (Wang et al., 2005). Furthermore, loss of either E-cadherin or DDR1 is sufficient to promote increased cortical contractility, resulting in the loss of cell-cell adhesion (Rhys et al., 2018). It has been shown that DDR1 and integrin α2β1 can up-regulate N-cadherin by interacting with transforming growth factor β-inducing protein I (TGFβI), to promote the growth, invasion and metastasis ().
Interestingly, expression of DDR1 can be regulated by secretory pathway Ca2 + -ATPase (SPCA2) through collagen I and miR-199B-5p (Sun et al., 2018; Wu et al., 2018). Studies have found that in DDR1 knockout mice, collagen deposition is reduced, and the stromal-vascular fraction (SVF) of adipose tissue is impaired. SVF secretes the cytokine Interleukin-6 (IL-6) in a DDR1-dependent manner, and SVF produced IL-6 increases tumor cell invasion in vitro ().
Tumor growth requires invading cancer cells to acquire mechanisms to penetrate a highly reactive collagen-rich stroma which possess anti-proliferative and pro-apoptotic properties. DDR binding to collagen in the microenvironment can regulate both apoptosis and tissue remodeling, through modulating the expression and activity of matrix metalloproteinases (MMPs). Binding of stromal type I collagen to DDR1 on tumor cells, triggers a signaling pathway culminating in the transcriptional up-regulation of pro-apoptotic Bcl-2-interacting killer (BIK), promoting cell growth suppression and central mediator of chondrocyte markers type I collagen (COL1)-induced apoptosis (Maquoi et al., 2012; Saby et al., 2019). In addition, membrane-bound matrix metalloproteinase membrane-type-1 matrix metalloproteinase (MT1-MMP) is highly expressed in invasive cells, including fibroblasts and invasive cancer cells, and promotes breast cancer tumorigenesis by inhibiting the apoptosis induced by the collagen/DDR1/BIK signaling axis (Liu et al., 2014). MT1-MMP acts through the degradation of collagen fibers and/or cleavage of the DDR1 receptor (). In addition, fibrillar collagen binding to DDR2 mediates MT1-MMP overexpression in fibroblasts (Majkowska et al., 2017). Knockdown of DDR2 inhibits collagen-induced MT1-MMP-dependent activation of pro-MMP-2, and the resultant upregulation of MT1-MMP expression (at both gene and protein levels).
After treatment with collagen and insulin, cells overexpressing DDR2 demonstrated both increased DDR2 p-Tyr740 and total tyrosine phosphorylation (Malcor et al., 2018). In osteoblasts DDR2 can activate the transcription factor Runx2, via the p38 MAPK signaling pathway, regulating differentiation (Zhang et al., 2015). Type I collagen activated DDR2 increases the stability of the EMT driving factor SNAIL1, promoting invasion and migration of breast cancer cells in vitro and metastasis in vivo (Zhang et al., 2013). Furthermore, in triple negative breast cancer, H-Ras promotes EMT by downregulation of DDR1 expression via its transcriptional repressor of ZEB1 (). In thyroid papillary cancer cells DDR2 activates ERK, increasing the stability of the EMT driving factor SNAIL1, reducing invasion and distant metastasis (Liang et al., 2017).
Collagen-Independent Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 Signaling
The DDRs do in fact have activity independent of collagen-binding and receptor kinase activity, which can be stimulated by integrin, TGF-β, and insulin receptors. This independent activation can alter both cell adhesion, and differentiation (Miller et al., 2017; Vella et al., 2019). Insulin receptor (IR-A) and insulin-like growth factor (IGF-I) can bind directly with DDRs, with IGF-I-DDR heterodimer activity independent of collagen binding. Activation of insulin-like growth factor/insulin-like growth factor receptor (IGF-I/IGF-IR) leads to up-regulation of G-protein estrogen receptor (GPER) and DDR1 expression (). IGF-1R, IGF-1, and insulin-like growth factor-2 (IGF-2) signaling through the PI3K/AKT/miR-199a-5p pathway up-regulates DDR1 (). DDR1 interacts with the Par3/Par6 cell polarity complex through the carboxyl terminal PDZ binding motif, and thus controls actin activity between cells (). While it has been shown that DDR1 knockout reduces insulin receptor expression (inhibiting proliferation and migration) (Vella et al., 2017), the inverse is also true in that an increase in DDR1 protein expression can be induced through IGF-I overexpression (Matà et al., 2016).
Discoidin Domain Receptor Tyrosine Kinase Dysregulation in Cancer
Dysregulation of DDR1 and DDR2 has been observed in many solid tumor types (including breast, ovarian, liver, gastric, colorectal, lung, brain, cervical, hematological, head and neck, melanoma, bladder, kidney, and prostate), and can be associated with aggressive metastatic tumors (including breast and ovarian) and a poor prognosis (; Yeh et al., 2019; ; Majo and Auguste, 2021). As discussed above, DDR dysregulation leads to many alterations which influence tumor development, pathology, and key clinical characteristics (key altered clinicopathological features being treatment response and prognosis) (; Mehta et al., 2021). DDR1 and DDR2 expression and dysregulation, in both physiological (e.g., development) and pathological conditions (including cancer, inflammation, and fibrosis), is summarized and highlighted in Figure 8 (). In the following sections we summarize some of the key breast and ovarian cancer focused research characterizing DDR1 and DDR2 dysregulation.
FIGURE 8
Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 in Breast Cancer
It has been shown that higher DDR1 protein expression is associated with breast cancer, promoting proliferation by suppressing antitumor immunity (Zhong et al., 2019). In the triple-negative breast cancer subtype (TNBC, or basal breast cancer) dysregulation of both DDR1 and DDR2 has been associated with increased invasion, and a poorer prognosis (Toy et al., 2015). In TNBC, collagen IV activated DDR1 induces increased cell surface expression of CD9, and secretion of metalloproteinases MMP-2 and MMP-9 which promote migration through the ECM (, ). Also in TNBC, co-expression of DDR1 and Protein phosphatase 1 regulatory subunit 1B (PPP1R1B, also known as DARPP-32) inhibits tumor cell migration (). Inhibition of DDR1 expression can significantly enhance the chemosensitivity of breast cancer cells to genotoxic treatments (Saby et al., 2019). Interestingly, DDR1 signaling has also been shown to enhance chemoresistance of breast cancer cells via NFκB-mediated expression of cyclooxygenase-2 (COX-2), and downregulation of DDR1 significantly enhanced drug sensitivity ().
Looking at associations with clinical breast cancer parameters, DDR1 protein expression was not significantly associated with either disease-free survival (DFS), or overall survival (OS) (Ren et al., 2013). However, in postmenopausal breast cancer patients, the specific DDR1 kinase domain mutation R776W does correlate closely with a poor prognosis (). The H-Ras pathway can cause mesenchymal-like phenotype changes in breast epithelial cells, and H-Ras inhibits DDR1 expression through ZEB1, a transcriptional inhibitor of DDR1. This H-Ras/ZEB1/DDR1 network interacts to promote tumor progression ().
Discoidin domain receptor Tyrosine Kinase 2 expression in breast cancer was found to be six times higher than in normal breast tissue, and importantly was a significant independent predictor of both recurrence and prognosis (Ren et al., 2013). Investigating DDR2 signaling pathways, the collagen-dependent protease pappalysin-1 (PAPP-1) plays a critical role in postpartum breast cancer, with increased IGF signaling resulting from PAPP-1-mediated degradation of IGFBP-4 and IGFBP-5, promoting DDR2 signaling (Slocum and Germain, 2019). Pregnancy-associated plasma protein-A (PAPP-A), overexpressed in more than 70% of breast cancers, activates DDR2 converting postpartum anti-proliferative collagen into tumor-promoting collagen (Slocum et al., 2019). DDR2 gene deletion in a breast cancer mouse models has been shown to increase anti-PD-1 therapy sensitivity, and the combination of anti-PD-1 and DDR2 tyrosinase inhibitor Dasatinib reduces tumor burden (Tu et al., 2019). Another inhibitor WRG-28 regulates DDR2, targeting the RTK extracellular domain, inhibiting the invasion of breast cancer cell migration (). Heat shock protein 47 (HSP47) can promote collagen maturation and deposition, and HSP47 expression in breast cancer cells enhances their invasive ability. Furthermore, HSP47 silencing can reduce the stability of DDR2, and inhibit the migration and invasion of (breast) cancer cells (). Breast Cancer-Associated Mesenchymal stem/multipotent stromal Cells (BC-MSC) can promote metastasis by increasing collagen deposition, with DDR2 up-regulation reported in MSC’s and in metastatic cancers (). In metastatic bone marrow mesenchymal hepatocytes DDR2 maintains the fibroblast phenotype, promotes collagen deposition, which enhances cell migration and metastatic capacity (). In stromal Cancer-Associated Fibroblasts (CAFs), DDR2 promotes ECM and collagen fibrous tissue deposition, and enhances tumor cell invasion and metastasis (). Beclin-1 (a critical regulator of autophagosome formation) regulates DDR2 expression, reducing both DDR2 expression and pro-inflammatory mediator IL-1β in breast cancer (Morikawa et al., 2015). It has been shown in breast cancer that DDR2 expression is associated with hypoxia marker HIF-1α expression, with DDR2 expression and phosphorylation increased under intra-tumoral hypoxic conditions (Ren et al., 2014). These findings implicate DDR2 in the development of hypoxia-induced breast cancer, and metastatic development.
Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 in Ovarian Cancer
It has been shown that DDR1 (protein) is highly expressed in serous ovarian cancers compared to normal ovarian epidermal tissues, with DDR1 mainly expressed in epithelial ovarian cancer (EOC) cells (). In EOC, the protein expression of DDR1, Claudin-3 (CLDN3) and epithelial cell adhesion molecule (Ep-CAM) are all significantly up-regulated, suggesting that this upregulation is an early driver event of EOC (). Furthermore, it has been shown that DDR1 over-expression is closely related to patients’ disease-free survival (DFS), with significantly higher DDR1 protein expression observed in high-grade and advanced tumors (Quan et al., 2011). In ovarian cancer tissues, expression of DDR1 is negatively correlated with the expression of miR-199a-3p, where miR-199a-3p inhibits DDR1 overexpression, drastically reducing the migration, invasiveness, and tumorigenicity of ovarian cancer cells ().
Discoidin domain receptor Tyrosine Kinase 2 is highly expressed in ovarian cancer tissues and has been shown to enhance the invasive ability of tumor cells (Zhao et al., 2011). DDR2 upregulation was detected in 103 ovarian cancer tissues, correlates with tumor stage and peritoneal metastasis, and is an independent prognostic factor (). Immunohistochemical detection of DDR2 in high-grade serous ovarian cancer (HGSOC) found DDR2 up-regulation in 14.10% (11 of 78) of cases (Ramalho et al., 2019). Investigating DDR2 signaling, collagen XIα1 is an ECM small fibrillar collagen regularly overexpressed in ovarian cancer (including cisplatin resistance or recurrent ovarian cancer) (Quan et al., 2011). Collagen XIα1 binding to both integrin α1β1 and DDR2 mediates chemoresistance by activating signaling that inhibits cisplatin-induced apoptosis in ovarian cancer cells (Rada et al., 2018). DDR2 expression can be induced by EMT factor Twist 1, promoting metastasis (). Further supporting a role for DDR2 in tumor development, knockdown of the tumor invasion regulator N-Myc Downstream Regulated 1 (NDRG1) enhanced tumor cell adhesion, migration and invasion activities (without affecting cell proliferation) and significantly increasing DDR2 expression (in ovarian and cervical cell lines) (Zhao et al., 2011).
Clinical Developments of Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 Targeted Therapy in Cancer
Interestingly, many DDR signaling pathways (including IGF-DDR) can be used to treat chronic inflammatory diseases, including cancer (Vella et al., 2019). While we have focused here on DDR1 and DDR2 in breast and ovarian cancer, they are increasingly important and relevant anti-cancer targets for multiple tumor types (; ; ). Previously Merestinib (LY2801653; inhibiting DDR1/2 and MET, MST1R, FLT3, AXL, MERTK, TEK, ROS1, and MKNK1/2) has shown potent anti-tumor activity in clinical trials against multiple advanced cancers (Yan et al., 2013). However, there is only a single trial (NCT03292536) directly evaluating the anti-tumor activity of Merestinib against metastatic breast cancer (and none against ovarian cancer) (Table 1). Additionally, currently only one other trial has included HR + HER2- Breast Cancers in its study design (NCT02791334).
TABLE 1
| No | Treatment ways | Target | NCT number | Title | Status | Conditions | Interventions | Phase | Study design | Enrollment | Study Start |
| 1 | Monotherapy | MET kinase inhibitor, anti-DDR1/2 | NCT032 92536 | Merestinib on bone metastases in subjects with breast cancer | Terminated | Bone metastases; breast cancer | Drug: Merestinib | Phase 1 | (1) Allocation: N/A; (2) Intervention model: Single group assignment; (3) Masking: None (open label); (4) Primary purpose: Treatment | 2 | January 11, 2018 |
| 2 | Combination therapy | MET kinase inhibitor, anti-DDR1/2 | NCT027 91334 | A study of anti-PD-L1 checkpoint antibody (LY3300054) alone and in combination in participants with advanced refractory solid tumors | Active, not recruiting | Solid tumor; microsatellite instability-high (MSI-H) solid tumor; cutaneous melanoma; pancreatic cancer; breast cancer (HR +HER2-) | Drug: LY3300054; drug: Ramucirumab; drug: Abemaciclib; drug: Merestinib; drug: LY3321367 | Phase 1 | (1) Allocation: Non-Randomized; (2) Intervention model: Parallel assignment; (3) Masking: None (open label); (4) Primary purpose: Treatment | (1) Allocation: Non-Randomized; (2) Intervention model: Parallel assignment; (3) Masking: None (open label); (4) Primary purpose: Treatment | June 29, 2016 |
Clinical trials of Merestinib targeting breast cancer.
Conclusion and Perspectives
The current body of fundamental research demonstrating the high expression of DDR1 and DDR2 in multiple female tumors suggests that DDRs play a significant role in tumorigenesis and regulate the occurrence and development of breast and ovarian cancers, influencing chemotherapeutic resistance and survival of tumor cells, and mediate cell invasion and metastases. As highlighted by work in other tumour types, the use of DDR1 and DDR2 targeting compounds holds significant promise for targeted anti-cancer treatment, as either mono or combinational therapeutics. Further fundamental research exploring DDR1 and DDR2 in breast and ovarian cancer is needed, to expand our knowledge of mechanisms driving progression in these cancers. It is anticipated that additional DDR1/2 targeted clinical trials will further strengthen the clinical case for the use of targeted DDR anti-cancer therapeutics, to improve outcomes for patients with either breast cancer or ovarian cancer.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
LC and XK: writing and editing. YF and SP: data curation. XW: investigation. EB and JB: methodology, writing, and editing. XL and JW: resources, funding acquisition, and project administration. All authors contributed to the article and approved the submitted version.
Funding
This work was partly supported by research grants from the National Natural Science Foundation of China (Nos. 81872160, 82072940, 82103047, 82102887, and 81802676), Beijing Natural Science Foundation of China (Nos. 7191009 and 7204293), National Key R&D Program of China (No. 2018YFC1312100), China National Key R&D (or Research and Development) Program (Nos. 2020AAA0105000 and 2020AAA0105004), Special Research Fund for Central Universities, Peking Union Medical College (No. 3332019053), Beijing Hope Run Special Fund of Cancer Foundation of China (Nos. LC2020L01, LC2019B03, and LC2019L07), Wuhan Youth Cadre Project (2017zqnlxr01 and 2017zqnlxr02), Clinical Research Physician Program of Tongji Medical College, HUST (5001540018), Golden Bridge Project Seed Fund of Beijing Association for Science and Technology (No. ZZ20004), Chinese Young Breast Experts Research Project (No. CYBER-2021-005), 2021 Chaoyang District Social Development Science and Technology Plan Project (Medical and Health Field) (No. CYSF2115), Beijing Xisike Clinical Oncology Research Foundation (No. Y-Young2021-0017), and XianSheng Clinical Research Special Fund of China International Medical Foundation (No. Z-2014-06-2103).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AgarwalG.SmithA. W.JonesB. (2019). Discoidin domain receptors: micro insights into macro assemblies.Biochim. Biophys. Acta Mol. Cell. Res.1866:118496. 10.1016/j.bbamcr.2019.06.010
2
AlvesF.VogelW.MossieK.MillauerB.HöflerH.UllrichA. (1995). Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer.Oncogene10609–618.
3
AssentD.BourgotI.HennuyB.GeurtsP.NoëlA.FoidartJ. M.et al (2015). A membrane-type-1 matrix metalloproteinase (MT1-MMP)-discoidin domain receptor 1 axis regulates collagen-induced apoptosis in breast cancer cells.PLoS One10:e0116006. 10.1371/journal.pone.0116006
4
AvinoS.De MarcoP.CirilloF.SantollaM. F.De FrancescoE. M.PerriM. G.et al (2016). Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells.Oncotarget752710–52728. 10.18632/oncotarget.10348
5
BarkerK. T.MartindaleJ. E.MitchellP. J.KamalatiT.PageM. J.PhippardD. J.et al (1995). Expression patterns of the novel receptor-like tyrosine kinase, DDR, in human breast tumours.Oncogene10569–575.
6
BaxH. J.JosephsD. H.PellizzariG.SpicerJ. F.MontesA.KaragiannisS. N. (2016). Therapeutic targets and new directions for antibodies developed for ovarian cancer.MAbs.81437–1455. 10.1080/19420862.2016.1219005
7
BelfioreA.MalaguarneraR.NicolosiM. L.LappanoR.RagusaM.MorrioneA.et al (2018). A novel functional crosstalk between DDR1 and the IGF axis and its relevance for breast cancer.Cell Adh. Migr.12305–314. 10.1080/19336918.2018.1445953
8
BonfilR. D.ChenW.VranicS.SohailA.ShiD.JangH.et al (2021). Expression and subcellular localization of discoidin domain receptor 1 (DDR1) define prostate cancer aggressiveness.Cancer Cell Int.21:507. 10.1186/s12935-021-02206-1
9
BorzaC. M.PozziA. (2014). Discoidin domain receptors in disease.Matrix Biol.34185–192. 10.1016/j.matbio.2013.12.002
10
CarafoliF.HohenesterE. (2013). Collagen recognition and transmembrane signalling by discoidin domain receptors.Biochim. Biophys. Acta18342187–2194. 10.1016/j.bbapap.2012.10.014
11
Castro-SanchezL.Soto-GuzmanA.Guaderrama-DiazM.Cortes-ReynosaP.SalazarE. P. (2011). Role of DDR1 in the gelatinases secretion induced by native type IV collagen in MDA-MB-231 breast cancer cells.Clin. Exp. Metastasis28463–477. 10.1007/s10585-011-9385-9
12
Castro-SanchezL.Soto-GuzmanA.Navarro-TitoN.Martinez-OrozcoR.SalazarE. P. (2010). Native type IV collagen induces cell migration through a CD9 and DDR1-dependent pathway in MDA-MB-231 breast cancer cells.Eur. J. Cell Biol.89843–852. 10.1016/j.ejcb.2010.07.004
13
ChenJ.WangS.ZhangZ.RichardsC. I.XuR. (2019). Heat shock protein 47 (HSP47) binds to discoidin domain-containing receptor 2 (DDR2) and regulates its protein stability.J. Biol. Chem.29416846–16854. 10.1074/jbc.RA119.009312
14
ChenL. Y.ZhiZ.WangL.ZhaoY. Y.DengM.LiuY. H.et al (2019). NSD2 circular RNA promotes metastasis of colorectal cancer by targeting miR-199b-5p-mediated DDR1 and JAG1 signalling.J. Pathol.248103–115. 10.1002/path.5238
15
ChungV. Y.TanT. Z.HuangR. L.LaiH. C.HuangR. Y. (2017). Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer.Gene.6359–15. 10.1016/j.gene.2017.09.001
16
CorsaC. A.BrenotA.GritherW. R.Van HoveS.LozaA. J.ZhangK.et al (2016). The action of discoidin domain receptor 2 in basal tumor cells and stromal cancer-associated fibroblasts is critical for breast cancer metastasis.Cell. Rep.152510–2523. 10.1016/j.celrep.2016.05.033
17
DasS.OngusahaP. P.YangY. S.ParkJ. M.AaronsonS. A.LeeS. W. (2006). Discoidin domain receptor 1 receptor tyrosine kinase induces cyclooxygenase-2 and promotes chemoresistance through nuclear factor-kappaB pathway activation.Cancer Res.668123–8130. 10.1158/0008-5472.CAN-06-1215
18
DejmekJ.DibK.JönssonM.AnderssonT. (2003). Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion.Int. J. Cancer103344–351. 10.1002/ijc.10752
19
DejmekJ.LeanderssonK.ManjerJ.BjartellA.EmdinS. O.VogelW. F.et al (2005). Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival.Clin. Cancer Res.11(2Pt1)520–528.
20
DengY.ZhaoF.HuiL.LiX.ZhangD.LinW.et al (2017). Suppressing miR-199a-3p by promoter methylation contributes to tumor aggressiveness and cisplatin resistance of ovarian cancer through promoting DDR1 expression.J. Ovarian Res.10:50. 10.1186/s13048-017-0333-4
21
DuZ.LovlyC. M. (2018). Mechanisms of receptor tyrosine kinase activation in cancer.Mol. Cancer17:58. 10.1186/s12943-018-0782-4
22
EmensL. A. (2018). Breast cancer immunotherapy: facts and hopes.Clin. Cancer Res.24511–520. 10.1158/1078-0432.CCR-16-3001
23
FanY.XuZ.FanJ.HuangL.YeM.ShiK.et al (2016). Prognostic significance of discoidin domain receptor 2 (DDR2) expression in ovarian cancer. Prognostic significance of discoidin domain receptor 2 (DDR2) expression in ovarian cancer.Am. J. Transl. Res.82845–2850.
24
GadiyaM.ChakrabortyG. (2018). Signaling by discoidin domain receptor 1 in cancer metastasis.Cell Adh. Migr.12315–323. 10.1080/19336918.2018.1520556
25
GaoY.ZhouJ.LiJ. (2021). Discoidin domain receptors orchestrate cancer progression: a focus on cancer therapies.Cancer Sci.112962–969. 10.1111/cas.14789
26
GhoshS.MarroccoI.YardenY. (2020). Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment.Adv. Cancer Res.1471–57. 10.1016/bs.acr.2020.04.002
27
GonzalezM. E.MartinE. E.AnwarT.Arellano-GarciaC.MedhoraN.LamaA.et al (2017). Mesenchymal stem Cell-Induced DDR2 mediates stromal-breast cancer interactions and metastasis growth.Cell. Rep.181215–1228. 10.1016/j.celrep.2016.12.079
28
GriffithO. L.SpiesN. C.AnuragM.GriffithM.LuoJ.TuD.et al (2018). The prognostic effects of somatic mutations in ER-positive breast cancer.Nat. Commun.9:3476. 10.1038/s41467-018-05914-x
29
GritherW. R.LongmoreG. D. (2018). Inhibition of tumor-microenvironment interaction and tumor invasion by small-molecule allosteric inhibitor of DDR2 extracellular domain.Proc. Natl. Acad. Sci. U.S.A.115E7786–E7794. 10.1073/pnas.1805020115
30
GritherW. R.DivineL. M.MellerE. H.WilkeD. J.DesaiR. A.LozaA. J.et al (2018). TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.Oncogene371714–1729. 10.1038/s41388-017-0043-9
31
HansenC.GreengardP.NairnA. C.AnderssonT.VogelW. F. (2006). Phosphorylation of DARPP-32 regulates breast cancer cell migration downstream of the receptor tyrosine kinase DDR1.Exp. Cell Res.3124011–4018. 10.1016/j.yexcr.2006.09.003
32
Heinzelmann-SchwarzV. A.Gardiner-GardenM.HenshallS. M.ScurryJ.ScolyerR. A.DaviesM. J.et al (2004). Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer.Clin. Cancer Res.104427–4436. 10.1158/1078-0432.CCR-04-0073
33
HenrietE.SalaM.Abou HammoudA.TuariihionoaA.Di MartinoJ.RosM.et al (2018). Multitasking discoidin domain receptors are involved in several and specific hallmarks of cancer.Cell Adh. Migr.12363–377. 10.1080/19336918.2018.1465156
34
Hidalgo-CarcedoC.HooperS.ChaudhryS. I.WilliamsonP.HarringtonK.LeitingerB.et al (2011). Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6.Nat. Cell Biol.1349–58. 10.1038/ncb2133
35
HuangH.SvobodaR. A.LazenbyA. J.SaowapaJ.ChaikaN.DingK.et al (2016). Up-regulation of N-cadherin by collagen i-activated discoidin domain receptor 1 in pancreatic cancer requires the adaptor molecule shc1.J. Biol. Chem.29123208–23223. 10.1074/jbc.M116.740605
36
Insua-RodríguezJ.OskarssonT. (2016). The extracellular matrix in breast cancer.Adv. Drug Deliv. Rev.9741–55. 10.1016/j.addr.2015.12.017
37
ItohY. (2018). Discoidin domain receptors: microenvironment sensors that promote cellular migration and invasion.Cell Adh. Migr.12378–385. 10.1080/19336918.2018.1460011
38
IwaiL. K.LuczynskiM. T.HuangP. H. (2014). Discoidin domain receptors: a proteomic portrait.Cell. Mol. Life Sci.713269–3279. 10.1007/s00018-014-1616-1
39
JiangY.XingX.LuS. (2009). The effect of suppressing discoidin domain receptor expression on keloid formation and proliferation.Wounds21207–214.
40
JingH.SongJ.ZhengJ. (2018). Discoidin domain receptor 1: new star in cancer-targeted therapy and its complex role in breast carcinoma.Oncol. Lett.153403–3408. 10.3892/ol.2018.7795
41
JohnsonJ. D.EdmanJ. C.RutterW. J. (1993). A receptor tyrosine kinase found in breast carcinoma cells has an extracellular discoidin I-like domain.Proc. Natl. Acad. Sci. U.S.A.905677–5681. 10.1073/pnas.90.12.5677
42
JulienS.BobowskiM.SteenackersA.Le BourhisX.DelannoyP. (2013). How do gangliosides regulate RTKs signaling?Cells2751–767. 10.3390/cells2040751
43
BhanumathyK. K.BalagopalA.VizeacoumarF. S.VizeacoumarF. J.FreywaldA.GiambraV. (2021). Protein tyrosine kinases: their roles and their targeting in leukemia.Cancers (Basel)13:184. 10.3390/cancers13020184
44
KimD.YouE.JeongJ.KoP.KimJ. W.RheeS. (2017). DDR2 controls the epithelial-mesenchymal-transition-related gene expression via c-Myb acetylation upon matrix stiffening.Sci. Rep.7:6847. 10.1038/s41598-017-07126-7
45
KimH. G.HwangS. Y.AaronsonS. A.MandinovaA.LeeS. W. (2019). Withdrawal: DDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation.J. Biol. Chem.294:18950. 10.1074/jbc.W119.011784
46
KohM.WooY.ValiathanR. R.JungH. Y.ParkS. Y.KimY. N.et al (2015). Discoidin domain receptor 1 is a novel transcriptional target of ZEB1 in breast epithelial cells undergoing H-Ras-induced epithelial to mesenchymal transition.Int. J. Cancer.136E508–E520. 10.1002/ijc.29154
47
KrohnJ. B.HutchesonJ. D.Martínez-MartínezE.IrvinW. S.BoutenC. V.BertazzoS.et al (2016). Discoidin domain receptor-1 regulates calcific extracellular vesicle release in vascular smooth muscle cell fibrocalcific response via transforming growth factor-β signaling.Arterioscler. Thromb. Vasc. Biol.36525–533. 10.1161/ATVBAHA.115.307009
48
LafitteM.SirventA.RocheS. (2020). Collagen kinase receptors as potential therapeutic targets in metastatic colon cancer.Front. Oncol.10:125. 10.3389/fonc.2020.00125
49
LeeJ. E.KangC. S.GuanX. Y.KimB. T.KimS. H.LeeY. M.et al (2007). Discoidin domain receptor 2 is involved in the activation of bone marrow-derived dendritic cells caused by type I collagen.Biochem. Biophys. Res. Commun.352244–250. 10.1016/j.bbrc.2006.11.010
50
LeitingerB.KwanA. P. (2006). The discoidin domain receptor DDR2 is a receptor for type X collagen.Matrix Biol.25355–364. 10.1016/j.matbio.2006.05.006
51
LemmonM. A.SchlessingerJ. (2010). Cell signaling by receptor tyrosine kinases.Cell.1411117–1134. 10.1016/j.cell.2010.06.011
52
LiN.DengY.ZhouL.TianT.YangS.WuY.et al (2019). Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: results from the Global Burden of Disease Study 2017.J. Hematol. Oncol.12:140. 10.2139/ssrn.3398545
53
LiangZ.XieW. J.ZhaoM.ChengG. P.WuM. J. (2017). DDR2 facilitates papillary thyroid carcinoma epithelial mesenchymal transition by activating ERK2/Snail1 pathway.Oncol. Lett.148114–8121. 10.3892/ol.2017.7250
54
LiuC.FengP.LiX.SongJ.ChenW. (2014). Expression of MMP-2. MT1-MMP, and TIMP-2 by cultured rabbit corneal fibroblasts under mechanical stretch.Exp. Biol. Med. (Maywood).239907–912. 10.1177/1535370214536650
55
MaennlingA. E.TurM. K.NiebertM.KlockenbringT.ZeppernickF.GattenlöhnerS.et al (2019). Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials.Cancers (Basel)11:E1826. 10.3390/cancers11121826
56
MahumudR. A.AlamK.DunnJ.GowJ. (2019). Emerging cancer incidence, mortality, hospitalisation and associated burden among Australian cancer patients, 1982-2014: an incidence-based approach in terms of trends, determinants and inequality.BMJ Open.9:e031874. 10.1136/bmjopen-2019-031874
57
MajkowskaI.ShitomiY.ItoN.GrayN. S.ItohY. (2017). Discoidin domain receptor 2 mediates collagen-induced activation of membrane-type 1 matrix metalloproteinase in human fibroblasts.J. Biol. Chem.2926633–6643. 10.1074/jbc.M116.770057
58
MajoS.AugusteP. (2021). The yin and yang of discoidin domain receptors (DDRs): implications in tumor growth and metastasis development.Cancers (Basel).13:1725. 10.3390/cancers13071725
59
MalcorJ. D.JuskaiteV.GavriilidouD.HunterE. J.DavidenkoN.HamaiaS.et al (2018). Coupling of a specific photoreactive triple-helical peptide to crosslinked collagen films restores binding and activation of DDR2 and VWF.Biomaterials18221–34. 10.1016/j.biomaterials.2018.07.050
60
MaquoiE.AssentD.DetilleuxJ.PequeuxC.FoidartJ. M.NoëlA. (2012). MT1-MMP protects breast carcinoma cells against type I collagen-induced apoptosis.Oncogene31480–493. 10.1038/onc.2011.249
61
MarastoniS.LigrestiG.LorenzonE.ColombattiA.MongiatM. (2008). Extracellular matrix: a matter of life and death.Connect. Tissue Res.49203–206. 10.1080/03008200802143190
62
MatàR.PalladinoC.NicolosiM. L.Lo PrestiA. R.MalaguarneraR.RagusaM.et al (2016). IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway.Oncotarget77683–7700. 10.18632/oncotarget.6524
63
MatchettK. B.Lynam-LennonN.WatsonR. W.BrownJ. A. L. (2017). Advances in precision medicine: tailoring individualized therapies.Cancers (Basel).9:146. 10.3390/cancers9110146
64
MehtaV.ChanderH.MunshiA. (2021). Complex roles of discoidin domain receptor tyrosine kinases in cancer.Clin. Transl. Oncol.231497–1510. 10.1007/s12094-021-02552-6
65
MillerM. A.SullivanR. J.LauffenburgerD. A. (2017). Molecular pathways: receptor ectodomain shedding in treatment, resistance, and monitoring of cancer.Clin. Cancer Res.23623–629. 10.1158/1078-0432.CCR-16-0869
66
MollS.DesmoulièreA.MoellerM. J.PacheJ. C.BadiL.ArcaduF.et al (2019). DDR1 role in fibrosis and its pharmacological targeting.Biochim. Biophys. Acta Mol. Cell Res.1866:118474. 10.1016/j.bbamcr.2019.04.004
67
MollS.YasuiY.AbedA.MurataT.ShimadaH.MaedaA.et al (2018). Selective pharmacological inhibition of DDR1 prevents experimentally-induced glomerulonephritis in prevention and therapeutic regime.J. Transl. Med.16:148. 10.1186/s12967-018-1524-5
68
MomenimovahedZ.TiznobaikA.TaheriS.SalehiniyaH. (2019). Ovarian cancer in the world: epidemiology and risk factors.Int. J. Womens Health11287–299. 10.2147/IJWH.S197604
69
MorikawaA.TakeuchiT.KitoY.SaigoC.SakurataniT.FutamuraM.et al (2015). Expression of beclin-1 in the microenvironment of invasive ductal carcinoma of the breast: correlation with prognosis and the cancer-stromal interaction.PLoS One10:e0125762. 10.1371/journal.pone.0125762
70
NakhjavaniM.HardinghamJ. E.PalethorpeH. M.PriceT. J.TownsendA. R. (2019). Druggable molecular targets for the treatment of triple negative breast cancer.J. Breast Cancer22341–361. 10.4048/jbc.2019.22.e39
71
OngusahaP. P.KimJ. I.FangL.WongT. W.YancopoulosG. D.AaronsonS. A.et al (2003). p53 induction and activation of DDR1 kinase counteract p53-mediated apoptosis and influence p53 regulation through a positive feedback loop.EMBO J.221289–1301. 10.1093/emboj/cdg129
72
OrgelJ. P. R. O.MadhurapantulaR. S. (2019). A structural prospective for collagen receptors such as DDR and their binding of the collagen fibril.Biochim. Biophys. Acta Mol. Cell Res.1866:118578. 10.1016/j.bbamcr.2019.04.008
73
PayneL. S.HuangP. H. (2014). Discoidin domain receptor 2 signaling networks and therapy in lung cancer.J. Thorac. Oncol.9900–904. 10.1097/JTO.0000000000000164
74
PengW. X.HuangJ. G.YangL.GongA. H.MoY. Y. (2017). Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer.Mol. Cancer16:161. 10.1186/s12943-017-0727-3
75
PerettiM.BadaouiM.GiraultA.Van GulickL.MabilleM. P.TebbakhaR.et al (2019). Original association of ion transporters mediates the ECM-induced breast cancer cell survival: Kv10.1-Orai1-SPCA2 partnership.Sci. Rep.9:1175. 10.1038/s41598-018-37602-7
76
PrakashA.Garcia-MorenoJ. F.BrownJ. A. L.BourkeE. (2018). Clinically applicable inhibitors impacting genome stability.Molecules.23:1166. 10.3390/molecules23051166
77
QuanJ.YahataT.AdachiS.YoshiharaK.TanakaK. (2011). Identification of receptor tyrosine kinase, discoidin domain receptor 1 (DDR1), as a potential biomarker for serous ovarian cancer.Int. J. Mol. Sci.12971–982. 10.3390/ijms12020971
78
RadaM.NallanthighalS.ChaJ.RyanK.SageJ.EldredC.et al (2018). Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.Oncogene374809–4820. 10.1038/s41388-018-0297-x
79
RamalhoS.AndradeL. A. A.FilhoC. C.NatalR. A.PavanelloM.FerraciniA. C.et al (2019). Role of discoidin domain receptor 2 (DDR2) and microRNA-182 in survival of women with high-grade serous ovarian cancer.Tumour Biol.41:1010428318823988. 10.1177/1010428318823988
80
RammalH.SabyC.MagnienK.Van-GulickL.GarnotelR.BuacheE.et al (2016). Discoidin domain receptors: potential actors and targets in cancer.Front. Pharmacol.7:55. 10.3389/fphar.2016.00346
81
RenT.ZhangJ.ZhangJ.LiuX.YaoL. (2013). Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients.Med. Oncol.30:397. 10.1007/s12032-012-0397-3
82
RenT.ZhangW.LiuX.ZhaoH.ZhangJ.ZhangJ.et al (2014). Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelial-mesenchymal transition programme under hypoxia.J. Pathol.234526–537. 10.1002/path.4415
83
RhysA. D.MonteiroP.SmithC.VaghelaM.ArnandisT.KatoT.et al (2018). Loss of E-cadherin provides tolerance to centrosome amplification in epithelial cancer cells.J. Cell Biol.217195–209. 10.1083/jcb.201704102
84
RuckertM. T.de AndradeP. V.SantosV. S.SilveiraV. S. (2019). Protein tyrosine phosphatases: promising targets in pancreatic ductal adenocarcinoma.Cell. Mol. Life Sci.762571–2592. 10.1007/s00018-019-03095-4
85
SabyC.CollinG.SinaneM.BuacheE.Van GulickL.SaltelF.et al (2019). DDR1 and MT1-MMP expression levels are determinant for triggering BIK-mediated apoptosis by 3D Type I collagen matrix in invasive basal-like breast carcinoma cells.Front. Pharmacol.10:462. 10.3389/fphar.2019.00462
86
SapiezynskiJ.TaratulaO.Rodriguez-RodriguezL.MinkoT. (2016). Precision targeted therapy of ovarian cancer.J. Control. Release243250–268. 10.1016/j.jconrel.2016.10.014
87
ShrivastavaA.RadziejewskiC.CampbellE.KovacL.McGlynnM.RyanT. E.et al (1997). An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors.Mol. Cell.125–34. 10.1016/S1097-2765(00)80004-0
88
SiegelR. L.MillerK. D.JemalA. (2020). Cancer statistics, 2020.CA Cancer J. Clin.707–30. 10.3322/caac.21590
89
SlocumE.GermainD. (2019). Collagen and PAPP-A in the etiology of postpartum breast cancer.Horm. Cancer.10137–144. 10.1007/s12672-019-00368-z
90
SlocumE.CraigA.VillanuevaA.GermainD. (2019). Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2.Breast Cancer Res.21:56. 10.1186/s13058-019-1142-z
91
SunX.GuptaK.WuB.ZhangD.YuanB.ZhangX.et al (2018). Tumor-extrinsic discoidin domain receptor 1 promotes mammary tumor growth by regulating adipose stromal interleukin 6 production in mice.J. Biol. Chem.2932841–2849. 10.1074/jbc.RA117.000672
92
TakaiK.DrainA. P.LawsonD. A.LittlepageL. E.KarpujM.KessenbrockK.et al (2018). Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers.Genes Dev.32244–257. 10.1101/gad.301366.117
93
ToyK. A.ValiathanR. R.NúñezF.KidwellK. M.GonzalezM. E.FridmanR.et al (2015). Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer.Breast Cancer Res. Treat.1509–18. 10.1007/s10549-015-3285-7
94
TuM. M.LeeF. Y. F.JonesR. T.KimballA. K.SaraviaE.GrazianoR. F.et al (2019). Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.Sci. Adv.5:eaav2437. 10.1126/sciadv.aav2437
95
ValiathanR. R.MarcoM.LeitingerB.KleerC. G.FridmanR. (2012). Discoidin domain receptor tyrosine kinases: new players in cancer progression.Cancer Metastasis Rev.31295–321. 10.1007/s10555-012-9346-z
96
VanajothiR.HemamaliniV.JeyakanthanJ.PremkumarK. (2019). Ligand-based pharmacophore mapping and virtual screening for identification of potential discoidin domain receptor 1 inhibitors.J. Biomol. Struct. Dyn.81–9. 10.1080/07391102.2019.1640132
97
VellaV.MalaguarneraR.NicolosiM. L.MorrioneA.BelfioreA. (2019). Insulin/IGF signaling and discoidin domain receptors: an emerging functional connection.Biochim. Biophys. Acta Mol. Cell. Res.1866:118522. 10.1016/j.bbamcr.2019.118522
98
VellaV.MalaguarneraR.NicolosiM. L.PalladinoC.SpoletiC.MassiminoM.et al (2017). Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells.Oncotarget843248–43270. 10.18632/oncotarget.18020
99
VogelW. (1999). Discoidin domain receptors: structural relations and functional implications.FASEB J.13S77–S82. 10.1096/fasebj.13.9001.s77
100
VogelW. F.AbdulhusseinR.FordC. E. (2006). Sensing extracellular matrix: an update on discoidin domain receptor function.Cell Signal.181108–1116. 10.1016/j.cellsig.2006.02.012
101
VogelW.GishG. D.AlvesF.PawsonT. (1997). The discoidin domain receptor tyrosine kinases are activated by collagen.Mol. Cell.113–23. 10.1016/S1097-2765(00)80003-9
102
WangC. Z.HsuY. M.TangM. J. (2005). Function of discoidin domain receptor I in HGF-induced branching tubulogenesis of MDCK cells in collagen gel.J. Cell. Physiol.203295–304. 10.1002/jcp.20227
103
WuA.ChenY.LiuY.LaiY.LiuD. (2018). miR-199b-5p inhibits triple negative breast cancer cell proliferation, migration and invasion by targeting DDR1.Oncol. Lett.164889–4896. 10.3892/ol.2018.9255
104
XuH.BihanD.ChangF.HuangP. H.FarndaleR. W.LeitingerB. (2012). Discoidin domain receptors promote α1β1- and α2β1-integrin mediated cell adhesion to collagen by enhancing integrin activation.PLoS One7:e52209. 10.1371/journal.pone.0052209
105
XuS.XuH.WangW.LiS.LiH.LiT.et al (2019). The role of collagen in cancer: from bench to bedside.J. Transl. Med.17:309. 10.1186/s12967-019-2058-1
106
YamaokaT.KusumotoS.AndoK.OhbaM.OhmoriT. (2018). Receptor tyrosine kinase-targeted cancer therapy.Int. J. Mol. Sci.19:3491. 10.3390/ijms19113491
107
YanS. B.PeekV. L.AjamieR.BuchananS. G.GraffJ. R.HeidlerS. A.et al (2013). LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.Invest. New Drugs.31833–844. 10.1007/s10637-012-9912-9
108
YehY. C.LinH. H.TangM. J. (2019). Dichotomy of the function of DDR1 in cells and disease progression.Biochim. Biophys. Acta Mol. Cell Res.1866:118473. 10.1016/j.bbamcr.2019.04.003
109
YehY. C.WangC. Z.TangM. J. (2009). Discoidin domain receptor 1 activation suppresses alpha2beta1 integrin-dependent cell spreading through inhibition of Cdc42 activity.J. Cell. Physiol.218146–156. 10.1002/jcp.21578
110
ZhangK.CorsaC. A.PonikS. M.PriorJ. L.Piwnica-WormsD.EliceiriK. W.et al (2013). The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis.Nat. Cell Biol.15677–687. 10.1038/ncb2743
111
ZhangY.SuJ.TengY.ZhangJ.WangJ.LiK.et al (2015). Nrp1, a neuronal regulator, enhances DDR2-ERK-Runx2 cascade in osteoblast differentiation via suppression of DDR2 degradation.Cell. Physiol. Biochem.3675–84. 10.1159/000374054
112
ZhaoG.ChenJ.DengY.GaoF.ZhuJ.FengZ.et al (2011). Identification of NDRG1-regulated genes associated with invasive potential in cervical and ovarian cancer cells.Biochem. Biophys. Res. Commun.408154–159. 10.1016/j.bbrc.2011.03.140
113
ZhongX.ZhangW.SunT. (2019). DDR1 promotes breast tumor growth by suppressing antitumor immunity.Oncol. Rep.422844–2854. 10.3892/or.2019.7338
114
ZhuD.HuangH.PinkasD. M.LuoJ.GangulyD.FoxA. E.et al (2019). 2-Amino-2,3-dihydro-1H-indene-5 -carboxamide-based discoidin domain receptor 1 (DDR1) inhibitors: design, synthesis, and in vivo antipancreatic cancer efficacy.J. Med. Chem.627431–7444. 10.1021/acs.jmedchem.9b00365
Summary
Keywords
discoidin domain receptor tyrosine kinases (DDR), receptor tyrosine kinase (RTK), protein tyrosine kinases (PTK), breast, ovarian, cancer, treatment, ECM
Citation
Chen L, Kong X, Fang Y, Paunikar S, Wang X, Brown JAL, Bourke E, Li X and Wang J (2021) Recent Advances in the Role of Discoidin Domain Receptor Tyrosine Kinase 1 and Discoidin Domain Receptor Tyrosine Kinase 2 in Breast and Ovarian Cancer. Front. Cell Dev. Biol. 9:747314. doi: 10.3389/fcell.2021.747314
Received
26 July 2021
Accepted
11 October 2021
Published
03 November 2021
Volume
9 - 2021
Edited by
Nejat Dalay, Istanbul University, Turkey
Reviewed by
Alice Hudder, Lake Erie College of Osteopathic Medicine, United States; Veronica Vella, University of Catania, Italy
Updates
Copyright
© 2021 Chen, Kong, Fang, Paunikar, Wang, Brown, Bourke, Li and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Emer Bourke, emer.bourke@nuigalway.ieXingrui Li, lixingrui@tjh.tjmu.edu.cnJing Wang, wangjing@cicams.ac.cn
‡These authors have contributed equally to this work
†ORCID: Li Chen, orcid.org/0000-0002-6989-1177; James A. L. Brown, orcid.org/0000-0002-3155-0334; Emer Bourke, orcid.org/0000-0002-2218-3114
This article was submitted to Epigenomics and Epigenetics, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.